Liquidia (NASDAQ:LQDA) Shares Down 3.1%

Liquidia Co. (NASDAQ:LQDAGet Free Report)’s share price was down 3.1% on Wednesday . The stock traded as low as $13.76 and last traded at $13.82. Approximately 171,331 shares traded hands during trading, a decline of 81% from the average daily volume of 887,989 shares. The stock had previously closed at $14.26.

Analyst Ratings Changes

A number of brokerages have recently weighed in on LQDA. HC Wainwright restated a “buy” rating and issued a $32.00 price objective on shares of Liquidia in a research note on Wednesday, May 15th. Needham & Company LLC reissued a “buy” rating and set a $28.00 price target on shares of Liquidia in a research report on Monday. One analyst has rated the stock with a sell rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, Liquidia currently has a consensus rating of “Moderate Buy” and a consensus target price of $21.00.

View Our Latest Stock Report on Liquidia

Liquidia Stock Performance

The stock has a market cap of $1.08 billion, a price-to-earnings ratio of -9.14 and a beta of 0.25. The business’s 50 day moving average is $13.45 and its 200-day moving average is $12.53.

Liquidia (NASDAQ:LQDAGet Free Report) last issued its quarterly earnings results on Monday, May 13th. The company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.22). Liquidia had a negative net margin of 674.42% and a negative return on equity of 177.83%. The company had revenue of $2.97 million during the quarter, compared to analysts’ expectations of $4.31 million. Sell-side analysts anticipate that Liquidia Co. will post -1.26 EPS for the current fiscal year.

Insider Activity

In other Liquidia news, General Counsel Russell Schundler sold 8,653 shares of Liquidia stock in a transaction on Monday, March 18th. The shares were sold at an average price of $15.82, for a total transaction of $136,890.46. Following the sale, the general counsel now owns 488,087 shares of the company’s stock, valued at approximately $7,721,536.34. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In related news, General Counsel Russell Schundler sold 8,653 shares of the company’s stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $15.82, for a total transaction of $136,890.46. Following the completion of the sale, the general counsel now owns 488,087 shares of the company’s stock, valued at approximately $7,721,536.34. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Michael Kaseta sold 3,136 shares of the stock in a transaction dated Friday, April 12th. The shares were sold at an average price of $14.58, for a total transaction of $45,722.88. Following the completion of the sale, the chief financial officer now owns 315,045 shares of the company’s stock, valued at approximately $4,593,356.10. The disclosure for this sale can be found here. Insiders have sold a total of 72,712 shares of company stock worth $1,125,576 over the last quarter. 31.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Liquidia

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Patient Square Capital LP purchased a new position in shares of Liquidia during the 1st quarter worth $105,942,000. Vanguard Group Inc. increased its position in Liquidia by 1.5% during the first quarter. Vanguard Group Inc. now owns 2,887,274 shares of the company’s stock worth $42,587,000 after purchasing an additional 43,352 shares during the last quarter. Kynam Capital Management LP raised its stake in Liquidia by 34.9% during the fourth quarter. Kynam Capital Management LP now owns 2,698,324 shares of the company’s stock worth $32,461,000 after purchasing an additional 698,324 shares during the period. Farallon Capital Management LLC acquired a new position in Liquidia in the 1st quarter valued at about $30,311,000. Finally, Vestal Point Capital LP purchased a new stake in shares of Liquidia in the 4th quarter valued at approximately $12,331,000. Institutional investors and hedge funds own 64.54% of the company’s stock.

About Liquidia

(Get Free Report)

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Read More

Receive News & Ratings for Liquidia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia and related companies with MarketBeat.com's FREE daily email newsletter.